SCTX — Scribe Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $330.17m
- $445.31m
- $51.17m
Annual income statement for Scribe Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 27.4 | 51.2 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 70.2 | 77.2 |
| Operating Profit | -42.8 | -26.1 |
| Total Net Non Operating Interest Income / Expense | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -37.6 | -23.6 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -47.8 | -21.8 |
| Net Income Before Extraordinary Items | ||
| Net Income | -47.8 | -21.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -47.8 | -21.8 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -2.72 | -1.24 |